HomeNewsBusinessDemand for health and hygiene products would remain high post pandemic: ITC's Sanjiv Puri

Demand for health and hygiene products would remain high post pandemic: ITC's Sanjiv Puri

ITC's gross revenue and PBT (before exceptional items) for FY20 stood at around Rs 46,300 crore and Rs 19,300 crore, respectively

September 07, 2020 / 18:56 IST
Story continues below Advertisement
ITC products (Image: Moneycontrol)
ITC products (Image: Moneycontrol)

In a post-pandemic world, demand for certain categories, like health and hygiene and packaged food, would remain at an elevated level, and ITC would be prepared to cater to that demand, said Sanjiv Puri, chairman and managing director, ITC on September 7.

"In the new normal, we are seeing a surge in certain categories. When the pandemic gets over, certain categories will settle at an elevated level. When I say elevated level, it is in comparison to pandemic situation, but may not have the surge seen during the pandemic. So health and hygiene could be one such category, but the awareness and importance of simple things like hand washing and cleanliness would definitely go up," said Puri at a virtual press interaction.

Story continues below Advertisement

He said the need to clean fruits and vegetables has been accentuated by the COVID-19 pandemic and with the availability of scientific solutions like ITC Nimwash, the demand for such things would increase going forward.

"Maybe sanitisers won't be at a level as today, but it will certainly be at an elevated level going forward. We also have to prepare now for the next normal... That's were the adaptability, creativity and resilience of the enterprises would be tested," Puri said.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show